Statement: patients from both arms of the primary trial experienced Grade 4 Neutropenia for the same amount of time. There was no recorded difference whatsoever. 
Primary_evidence: Outcome Measurement:    Duration in Days of Grade 4 Neutropenia in Chemotherapy Cycle 1   Eligible subjects were randomized in a 1:1 ratio. Subjects were dosed with either the F 627 20 mg/dose PFS or Neulasta® 6 mg/dose as the study drug in each chemotherapy cycle. Subjects remained in their assigned treatment arm throughout the study. Subjects were dosed subcutaneously (SC) 24 to 28 hours after receiving TC chemotherapy (75 mg/m2 docetaxel + 600 mg/m2 cyclophosphamide) on Day 2 of each chemotherapy cycle that the subject underwent (up to 4 cycles). Grade 4 (severe) neutropenia was defined as ANC <0.5 × 109/L within the first 12 days of chemotherapy.   Time frame: The first of 4, 21-day chemotherapy cycles (average 3 weeks) Results 1:    Arm/Group Title: F-627   Arm/Group Description: F-627, 20 mg fixed dose pre-filled syringe, administered on Day 2 of each of 4 chemotherapy cycles.   F-627: single dose pre-filled syringe   Overall Number of Participants Analyzed: 197   Mean (Standard Deviation)   Unit of Measure: days  0.2         (0.51) Results 2:    Arm/Group Title: Neulasta   Arm/Group Description: 6 mg fixed dose Neulasta  , administered on Day 2 of each of 4 chemotherapy cycles   Neulasta: single dose pre-filled syringe   Overall Number of Participants Analyzed: 196   Mean (Standard Deviation)   Unit of Measure: days  0.2         (0.45)